We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

QIAGEN

Qiagen is a provider of sample and assay technologies for molecular diagnostics and applied testing, including comple... read more Featured Products: More products

Download Mobile App




Digital PCR Assays Support Surveillance of Bundibugyo Ebolavirus Outbreak

By LabMedica International staff writers
Posted on 29 May 2026

QIAGEN (Venlo, Netherlands) has introduced two custom-designed research-use-only (RUO) QIAcuity dPCR assays to support infectious disease research and surveillance connected to the Bundibugyo ebolavirus outbreak. More...

The assays are designed for integration with the QIAcuity digital PCR system and for use by qualified laboratories in research, wastewater surveillance, and other environmental monitoring workflows. They were developed using publicly available genomic sequence information released during the outbreak response.

The new assays target the nucleoprotein (NP) and VP35 regions of the virus. Initial in silico sequence analysis showed no mismatches against the currently published outbreak sequences reviewed by the company. On the QIAcuity platform, dPCR enables sensitive nucleic acid detection and quantification across research applications, including infectious disease research and environmental surveillance, and the assays are part of a broader Sample to Insight portfolio that spans sample preparation through sequencing and analysis.

The assays are intended strictly for research use and are not intended for diagnostic procedures. They are available through a custom assay workflow on a make-to-order basis targeting the NP and VP35 regions. Complementary products available from stock include QIAseq sequencing panels and sample preparation and molecular workflow kits to support nucleic acid processing for downstream dPCR and next-generation sequencing (NGS).

The availability of these tools highlights the role of adaptable molecular technologies in supporting public health research infrastructure as genomic information emerges during outbreak responses. Combined with the QIAcuity system, the portfolio enables laboratories to rapidly adapt existing workflows as new pathogen targets arise. 

“Public health preparedness depends on the ability of laboratories to evaluate emerging pathogen targets as reliable genomic information becomes available,” said Thierry Bernard, Chief Executive Officer of QIAGEN. “QIAGEN is committed to supporting customers around the world with adaptable molecular technologies that help strengthen infectious disease research and surveillance capacity. Our goal remains clear: no country should be left behind when new threats emerge.” 



Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
Online QC Software
Acusera 24•7
Repetitive Pipette
VWR® Stepper Pro
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Capillary testing on the Atellica analyzers supports the most common laboratory testing needs (Photo courtesy of Siemens Healthineers)

Siemens Adds CE-Marked Capillary Claims for 24 Assays on Atellica Analyzers

Venous blood draws can be challenging in patients with difficult veins, needle phobia, or limited blood volume, and they can slow collection in busy services. Core laboratories also face pressure to expand... Read more

Immunology

view channel
Image: New findings show unique pathogen‑directed antibody patterns are already present years ahead of a formal diagnosis of inflammatory bowel disease (Image Credit: iStock)

Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.